课题基金 / 基金详情

Development of Inhibitors Targeting Flavivirus Methyltransferase

Development of Inhibitors Targeting Flavivirus Methyltransferase
黄病毒甲基转移酶抑制剂的开发
批准号:
10636605
负责人:
HONGMIN LI
金额:
$76.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-07 至 2028-03-31

项目摘要

项目成果

HONGMIN LI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract: Flaviviruses are primarily insect-borne, associated with global morbidity and mortality, and found on every inhabited continent. Unfortunately, current therapeutic options for treating diseases associated with these viruses are limited. All flaviviruses encode methyltransferases (MTases)—flaviviral NS5 for both N-7 and 2'-O methylations of viral genomic RNA. The N-7 MTase function is essential for replication of the viral RNA genome, whereas 2'-O MTase function is required for the virus to evade the host innate immune response. These activities are conserved among the flaviviruses. For this project, our collaborative team will optimize the current lead compounds, perform high throughput screening (HTS) to identify additional lead candidates, chemically optimize the lead candidates, and define structure activity relationships. Optimizing current lead compounds using cutting- edge medicinal chemistry, the team will perform a large scale HTS campaign using innovative fluorescence chemical probes to identify additional small molecule inhibitors of flavivirus RNA capping MTases. We will perform an in-depth investigation of the model of action and antiviral efficacy using in vitro biochemistry, structural biology, virology, in vivo pharmacokinetics, and in vivo animal models, which will allow the development of novel, effective, broad-spectrum, and druglike therapeutic agents against both flaviviruses. Preliminary progress has been made in the identification of initial lead inhibitors of these MTases, demonstrating low nanomolar antiviral activity. We will advance these compounds to further develop potent antiviral compounds while conducting large- scale screening in parallel for additional structural scaffold discoveries. Complementary expertise among our investigators will synergize and expedite the progress of this research. Our collaborative objective is to provide first-in-class drug candidates for the treatment or prevention of these viral infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of therapeutics against Cryptococcosis by Repurposing Pharmaceutical Libraries
  • 批准号:
    10308245
  • 项目类别:
  • 资助金额:
    $16.14万
  • 财政年份:
    2019
  • 负责人:
    HONGMIN LI
  • 依托单位:
High throughput screening of the Prp8 intein splicing inhibitors for pathogenic fungi
  • 批准号:
    10319642
  • 项目类别:
  • 资助金额:
    $58.27万
  • 财政年份:
    2018
  • 负责人:
    HONGMIN LI
  • 依托单位:
High throughput screening of orthosteric inhibitors of flavivirus protease
  • 批准号:
    10376239
  • 项目类别:
  • 资助金额:
    $55.0万
  • 财政年份:
    2018
  • 负责人:
    HONGMIN LI
  • 依托单位:
High throughput screening of orthosteric inhibitors of flavivirus protease
  • 批准号:
    10318299
  • 项目类别:
  • 资助金额:
    $56.34万
  • 财政年份:
    2018
  • 负责人:
    HONGMIN LI
  • 依托单位:
海外基金